» Articles » PMID: 36626901

Human Cortical Interneurons Optimized for Grafting Specifically Integrate, Abort Seizures, and Display Prolonged Efficacy Without Over-inhibition

Abstract

Previously, we demonstrated the efficacy of human pluripotent stem cell (hPSC)-derived GABAergic cortical interneuron (cIN) grafts in ameliorating seizures. However, a safe and reliable clinical translation requires a mechanistic understanding of graft function, as well as the assurance of long-term efficacy and safety. By employing hPSC-derived chemically matured migratory cINs in two models of epilepsy, we demonstrate lasting efficacy in treating seizures and comorbid deficits, as well as safety without uncontrolled growth. Host inhibition does not increase with increasing grafted cIN densities, assuring their safety without the risk of over-inhibition. Furthermore, their closed-loop optogenetic activation aborted seizure activity, revealing mechanisms of graft-mediated seizure control and allowing graft modulation for optimal translation. Monosynaptic tracing shows their extensive and specific synaptic connections with host neurons, resembling developmental connection specificity. These results offer confidence in stem cell-based therapy for epilepsy as a safe and reliable treatment for patients suffering from intractable epilepsy.

Citing Articles

Overcoming Graft Rejection in Induced Pluripotent Stem Cell-Derived Inhibitory Interneurons for Drug-Resistant Epilepsy.

Beaudreault C, Wang R, Muh C, Rosenberg A, Funari A, McGoldrick P Brain Sci. 2024; 14(10).

PMID: 39452039 PMC: 11506040. DOI: 10.3390/brainsci14101027.


Understanding epileptogenesis from molecules to network alteration.

Park K Encephalitis. 2024; 4(3):47-54.

PMID: 38886161 PMC: 11237188. DOI: 10.47936/encephalitis.2024.00038.


In and out: Benchmarking in vitro, in vivo, ex vivo, and xenografting approaches for an integrative brain disease modeling pipeline.

Pereira M, Shyti R, Testa G Stem Cell Reports. 2024; 19(6):767-795.

PMID: 38865969 PMC: 11390705. DOI: 10.1016/j.stemcr.2024.05.004.


Cell-specific extracellular vesicle-encapsulated exogenous GABA controls seizures in epilepsy.

R A, K S, Chandran D, Hegde S, Upadhya R, Se P Stem Cell Res Ther. 2024; 15(1):108.

PMID: 38637847 PMC: 11027552. DOI: 10.1186/s13287-024-03721-4.


GABAergic Interneuron Cell Therapy for Drug-Resistant Epilepsy.

Chen J, Li Z, Wang Y, Chen L Neurosci Bull. 2024; 40(5):680-682.

PMID: 38491232 PMC: 11127856. DOI: 10.1007/s12264-024-01195-1.


References
1.
Berg A . Identification of pharmacoresistant epilepsy. Neurol Clin. 2009; 27(4):1003-1013. PMC: 2827183. DOI: 10.1016/j.ncl.2009.06.001. View

2.
Rho J, Boison D . The metabolic basis of epilepsy. Nat Rev Neurol. 2022; 18(6):333-347. PMC: 10259193. DOI: 10.1038/s41582-022-00651-8. View

3.
Piao J, Zabierowski S, Dubose B, Hill E, Navare M, Claros N . Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01. Cell Stem Cell. 2021; 28(2):217-229.e7. PMC: 7903922. DOI: 10.1016/j.stem.2021.01.004. View

4.
Singh A, Trevick S . The Epidemiology of Global Epilepsy. Neurol Clin. 2016; 34(4):837-847. DOI: 10.1016/j.ncl.2016.06.015. View

5.
Xu H, Wang B, Ono M, Kagita A, Fujii K, Sasakawa N . Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility. Cell Stem Cell. 2019; 24(4):566-578.e7. DOI: 10.1016/j.stem.2019.02.005. View